JP2022512735A - 肝疾患を治療するための組成物および方法 - Google Patents

肝疾患を治療するための組成物および方法 Download PDF

Info

Publication number
JP2022512735A
JP2022512735A JP2021521144A JP2021521144A JP2022512735A JP 2022512735 A JP2022512735 A JP 2022512735A JP 2021521144 A JP2021521144 A JP 2021521144A JP 2021521144 A JP2021521144 A JP 2021521144A JP 2022512735 A JP2022512735 A JP 2022512735A
Authority
JP
Japan
Prior art keywords
wisp1
antibody
liver
liver disease
mir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2021521144A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512735A5 (https=
JPWO2020081920A5 (https=
Inventor
ユンソク チェ，マイケル
Original Assignee
ザ ジェネラル ホスピタル コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジェネラル ホスピタル コーポレイション filed Critical ザ ジェネラル ホスピタル コーポレイション
Publication of JP2022512735A publication Critical patent/JP2022512735A/ja
Publication of JP2022512735A5 publication Critical patent/JP2022512735A5/ja
Publication of JPWO2020081920A5 publication Critical patent/JPWO2020081920A5/ja
Priority to JP2024163238A priority Critical patent/JP2025011102A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
JP2021521144A 2018-10-19 2019-10-18 肝疾患を治療するための組成物および方法 Withdrawn JP2022512735A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024163238A JP2025011102A (ja) 2018-10-19 2024-09-20 肝疾患を治療するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862747903P 2018-10-19 2018-10-19
US62/747,903 2018-10-19
PCT/US2019/056910 WO2020081920A1 (en) 2018-10-19 2019-10-18 Compositions and methods for treatment of liver disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024163238A Division JP2025011102A (ja) 2018-10-19 2024-09-20 肝疾患を治療するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2022512735A true JP2022512735A (ja) 2022-02-07
JP2022512735A5 JP2022512735A5 (https=) 2022-10-25
JPWO2020081920A5 JPWO2020081920A5 (https=) 2022-10-25

Family

ID=70284106

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021521144A Withdrawn JP2022512735A (ja) 2018-10-19 2019-10-18 肝疾患を治療するための組成物および方法
JP2024163238A Pending JP2025011102A (ja) 2018-10-19 2024-09-20 肝疾患を治療するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024163238A Pending JP2025011102A (ja) 2018-10-19 2024-09-20 肝疾患を治療するための組成物および方法

Country Status (9)

Country Link
US (2) US20210388073A1 (https=)
EP (1) EP3866852A4 (https=)
JP (2) JP2022512735A (https=)
KR (1) KR20210081366A (https=)
CN (2) CN120305401A (https=)
AU (1) AU2019361120A1 (https=)
CA (1) CA3117098A1 (https=)
IL (1) IL282251A (https=)
WO (1) WO2020081920A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3154648A1 (en) 2019-09-16 2021-03-25 Opsidio, LLC Anti-stem cell factor antibodies and methods of use thereof
US20220378843A1 (en) * 2019-11-01 2022-12-01 Figene, Llc Fibroblast-based therapy for treatment of sclerosing cholangitis
CN117487010B (zh) * 2022-08-02 2025-02-14 东莞市朋志生物科技有限公司 抗四碘甲状腺素抗体或其功能性片段、检测四碘甲状腺素的试剂和试剂盒
AU2024232439A1 (en) * 2023-03-03 2025-08-28 Karydo Therapeutix, Inc. Antibody or antigen-binding fragment of same
CN117045680B (zh) * 2023-10-12 2023-12-08 北京国卫生物科技有限公司 促进肝脏再生的干细胞制剂及其制备方法
WO2025179048A2 (en) * 2024-02-20 2025-08-28 Ecogenome Llc Antibodies that bind dach1 and methods of use
CN119331100B (zh) * 2024-10-16 2025-07-25 天津大学 特异性结合25-羟基维生素d的单克隆抗体及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064478A1 (en) * 1999-04-27 2000-11-02 Mitsubishi Pharma Corporation Preventives/remedies for liver diseases
WO2003014345A1 (fr) * 2001-08-08 2003-02-20 Ajinomoto Co., Inc. Ensemble de genes participant a l'activation des astrocytes du foie
JP2013531487A (ja) * 2010-06-02 2013-08-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド 肝線維症治療用組成物および肝線維症の治療法
JP2017513854A (ja) * 2014-04-15 2017-06-01 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｗｉｓｐ１に結合する抗原結合タンパク質
WO2017201422A1 (en) * 2016-05-20 2017-11-23 The General Hospital Corporation Using micrornas to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2014770A3 (en) * 1997-10-29 2009-02-18 Genentech, Inc. WNT-1 Iinduced secreted polypeptide WISP-2
AU2015360502A1 (en) * 2014-12-10 2017-06-29 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000064478A1 (en) * 1999-04-27 2000-11-02 Mitsubishi Pharma Corporation Preventives/remedies for liver diseases
WO2003014345A1 (fr) * 2001-08-08 2003-02-20 Ajinomoto Co., Inc. Ensemble de genes participant a l'activation des astrocytes du foie
JP2013531487A (ja) * 2010-06-02 2013-08-08 アルナイラム ファーマシューティカルズ， インコーポレイテッド 肝線維症治療用組成物および肝線維症の治療法
JP2017513854A (ja) * 2014-04-15 2017-06-01 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｗｉｓｐ１に結合する抗原結合タンパク質
WO2017201422A1 (en) * 2016-05-20 2017-11-23 The General Hospital Corporation Using micrornas to control activation status of hepatic stellate cells and to prevent fibrosis in progressive liver diseases

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ARCH. MED. SCI., vol. 11, no. 3, JPN6023038722, 2015, pages 647 - 653, ISSN: 0005327300 *
JOURNAL OF HEPATOLOGY, vol. 68, no. 1, JPN6023038723, April 2018 (2018-04-01), pages 614 - 615, ISSN: 0005158741 *
肝胆膵, vol. 53（3）, JPN6024018745, 2006, pages 349 - 355, ISSN: 0005327303 *
肝胆膵, vol. 57(2), JPN6024018743, 2008, pages 259 - 267, ISSN: 0005327301 *
肝胆膵, vol. 60(6), JPN6024018744, 2010, pages 1033 - 1040, ISSN: 0005327302 *

Also Published As

Publication number Publication date
JP2025011102A (ja) 2025-01-23
US20210388073A1 (en) 2021-12-16
WO2020081920A1 (en) 2020-04-23
AU2019361120A1 (en) 2021-05-13
CN120305401A (zh) 2025-07-15
IL282251A (en) 2021-05-31
EP3866852A4 (en) 2022-07-06
EP3866852A1 (en) 2021-08-25
KR20210081366A (ko) 2021-07-01
US20250223344A1 (en) 2025-07-10
CA3117098A1 (en) 2020-04-23
CN113271971A (zh) 2021-08-17

Similar Documents

Publication Publication Date Title
JP2022512735A (ja) 肝疾患を治療するための組成物および方法
US20240002488A1 (en) Method of treating or preventing liver conditions
KR20170080604A (ko) 항-인터류킨-33 항체 및 그것의 용도
JP6633029B2 (ja) 血管新生障害の処置
AU2018364630A1 (en) Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
KR20210142638A (ko) Cd3 항원 결합 단편 및 이의 응용
EP2882456B1 (en) Use of il-20 antagonists for treating liver diseases
EP1661582A1 (en) Cancer metastasis inhibitor
US20250129170A1 (en) Epo receptor agonists and antagonists
TWI654996B (zh) 微核糖核酸let-7及轉形生長因子β第三類受體調控軸作為心臟損傷標的之用途
JP2024540595A (ja) 強皮症疾患の治療方法
US20230416375A1 (en) Antibody variants against wnt receptor ryk
US20260035468A1 (en) New anti-itgb8 antibodies and its uses thereof
US20260116986A1 (en) Epo receptor agonists and antagonists
US20250326831A1 (en) Methods for treating disease using psmp antagonists
CN117751141A (zh) 用于预防或治疗癌症的抗cd300c单克隆抗体及其生物标志物
WO2016172082A1 (en) A therapeutic gene cocktail for heart regeneration
SE2350695A1 (en) Binding agents
BR112020006860A2 (pt) composição para depleção de células t citotóxicas

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230926

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240226

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240920

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241101

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20241125